New Clinical Study Confirms Chromium Picolinate’s Positive Effects in People With Type 2 Diabetes & Insulin Resistance Efficacy Demonstrated in Over 10 Published Human Studies

PURCHASE, N.Y., April 23, 2003 – Nutrition 21, Inc. (Nasdaq: NXXI) announced that a recently published study in the Journal of Nutritional Biochemistry shows that chromium picolinate supplementation significantly improved insulin function and glucose control in people with type 2 diabetes.

The double-blind, placebo-controlled, crossover study, led by Basudev Bhattacharya from Calcutta’s University College of Medicine, evaluated the effects of chromium picolinate (400 mcg of chromium per day) in 43 people with type 2 diabetes. Significant improvements were seen after 12 weeks of chromium administration (change in: fasting glucose = -0.44 mmol/L, p<0.001; post-prandial glucose = -1.97 mmol/L, p<0.001; decrease in fasting insulin, p<0.05; compared to placebo).

This clinical study adds to a growing body of evidence that prompted Richard Anderson, Ph.D., U.S. Department of Agriculture’s Beltsville Human Nutrition Research Center, to comment, “the overwhelming majority of studies using chromium picolinate supplementation for impaired glucose tolerance and diabetes have shown a positive effect.” Dr. Anderson presented at a recent scientific summit hosted by non-profit Council for the Advancement of Diabetes Research and Education (CADRE) entitled, “Chromium in Health and Disease,” held in Boston.
At the CADRE summit, presentations included the latest epidemiological, preclinical and clinical data on the role of chromium and chromium picolinate supplementation in insulin resistance. Insulin resistance is associated with type 2 diabetes, obesity, cardiovascular disease, polycystic ovarian syndrome (PCOS) and depression. “In the context of the CADRE summit and a substantial body of published research, this study by Bhattacharya and colleagues is exciting and substantiates earlier studies conducted in the U.S., China and other countries,” added Anderson.

It is estimated that 95 million Americans have some degree of insulin resistance and over 17 million Americans have type 2 diabetes. “Several of the scientific investigators at the CADRE summit announced that additional trials using Chromax chromium picolinate are now underway in the U.S. We believe that the results of these trials will continue to build consensus regarding chromium picolinate’s beneficial effects in restoring the metabolic pathways inhibited by insulin resistance,” states James Komorowski, M.S., VP of Technical Services and Scientific Affairs, Nutrition 21, Inc., the source of Chromax® chromium picolinate.

Chromium is an essential mineral that is a co-factor of insulin. As diabetes, obesity and cardiovascular disease associated with insulin resistance reach epidemic proportions, healthcare practitioners are increasingly eager to provide patients with safe, efficacious and cost-effective complementary interventions to support the health of their patients. Chromax chromium picolinate is the most clinically tested brand of chromium with proven efficacy for support of glucose metabolism. Chromax is available through or by calling 1-866-CHROMAX.

About Nutrition 21

Nutrition 21 is a leading developer and provider of nutritional products whose health benefits are substantiated by clinical research. The Company markets Chromax chromium picolinate, the leading brand of chromium, and holds 35 patents for nutrition products, 22 for chromium compounds and their uses. More information is available at

# # #

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.